CA3101335C - Fused thiophene compounds - Google Patents
Fused thiophene compounds Download PDFInfo
- Publication number
- CA3101335C CA3101335C CA3101335A CA3101335A CA3101335C CA 3101335 C CA3101335 C CA 3101335C CA 3101335 A CA3101335 A CA 3101335A CA 3101335 A CA3101335 A CA 3101335A CA 3101335 C CA3101335 C CA 3101335C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- optionally substituted
- mmol
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684495P | 2018-06-13 | 2018-06-13 | |
| US62/684,495 | 2018-06-13 | ||
| PCT/US2019/036581 WO2019241271A1 (en) | 2018-06-13 | 2019-06-11 | Fused thiophene compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3101335A1 CA3101335A1 (en) | 2019-12-19 |
| CA3101335C true CA3101335C (en) | 2024-01-09 |
Family
ID=67263033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3101335A Active CA3101335C (en) | 2018-06-13 | 2019-06-11 | Fused thiophene compounds |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11191769B2 (https=) |
| EP (1) | EP3807283A1 (https=) |
| JP (1) | JP7365059B2 (https=) |
| CN (1) | CN112601751B (https=) |
| AU (1) | AU2019284605A1 (https=) |
| CA (1) | CA3101335C (https=) |
| TW (1) | TWI826463B (https=) |
| WO (1) | WO2019241271A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| AU2020387392B2 (en) | 2019-11-19 | 2025-09-11 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of Helios protein |
| WO2021155050A1 (en) * | 2020-01-29 | 2021-08-05 | Biotheryx, Inc. | Kinase modulators, pharmaceutical compositions, and therapeutic applications |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| WO2022061348A1 (en) | 2020-09-16 | 2022-03-24 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN116583509A (zh) * | 2020-10-07 | 2023-08-11 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| TW202237580A (zh) | 2020-12-14 | 2022-10-01 | 美商拜歐斯瑞克斯公司 | Pde4降解劑、醫藥組合物及治療應用 |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| BR112023020077A2 (pt) | 2021-04-06 | 2023-11-14 | Bristol Myers Squibb Co | Compostos de oxoisoindolina substituída por piridinila |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| WO2024015855A1 (en) | 2022-07-13 | 2024-01-18 | Monte Rosa Therapeutics, Inc. | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS |
| CN120303264A (zh) | 2022-09-09 | 2025-07-11 | 医诺康治疗公司 | CK1α和双重CK1α/GSPT1降解化合物 |
| WO2024222918A1 (zh) * | 2023-04-28 | 2024-10-31 | 中国药科大学 | 一种苯并六元杂环类gspt1蛋白降解剂及其应用 |
| CN119371398A (zh) * | 2023-07-25 | 2025-01-28 | 安道麦阿甘有限公司 | 用于制备噻吩酮的新路线 |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| CN101186611B (zh) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
| KR20170042598A (ko) | 2014-08-22 | 2017-04-19 | 셀진 코포레이션 | 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 |
| AU2016266942B2 (en) * | 2015-05-22 | 2018-10-18 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| CA3043938A1 (en) * | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
-
2019
- 2019-06-11 CN CN201980039027.2A patent/CN112601751B/zh active Active
- 2019-06-11 CA CA3101335A patent/CA3101335C/en active Active
- 2019-06-11 AU AU2019284605A patent/AU2019284605A1/en not_active Abandoned
- 2019-06-11 US US16/438,244 patent/US11191769B2/en active Active
- 2019-06-11 WO PCT/US2019/036581 patent/WO2019241271A1/en not_active Ceased
- 2019-06-11 EP EP19739747.4A patent/EP3807283A1/en not_active Withdrawn
- 2019-06-11 JP JP2020569169A patent/JP7365059B2/ja active Active
- 2019-06-13 TW TW108120511A patent/TWI826463B/zh not_active IP Right Cessation
-
2021
- 2021-12-06 US US17/457,733 patent/US20220088025A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN112601751B (zh) | 2024-04-02 |
| US20220088025A1 (en) | 2022-03-24 |
| EP3807283A1 (en) | 2021-04-21 |
| JP2021527098A (ja) | 2021-10-11 |
| WO2019241271A1 (en) | 2019-12-19 |
| TW202000674A (zh) | 2020-01-01 |
| AU2019284605A1 (en) | 2020-12-10 |
| CN112601751A (zh) | 2021-04-02 |
| US11191769B2 (en) | 2021-12-07 |
| US20200000814A1 (en) | 2020-01-02 |
| JP7365059B2 (ja) | 2023-10-19 |
| TWI826463B (zh) | 2023-12-21 |
| CA3101335A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3101335C (en) | Fused thiophene compounds | |
| US11400084B2 (en) | Aminoamide compounds | |
| US10889593B2 (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
| CA3119343C (en) | Substituted isoindolinones | |
| US9938302B2 (en) | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | |
| US11236103B2 (en) | Bifunctional compounds | |
| CA3094988A1 (en) | Thienopyrimidinone compounds | |
| WO2019173224A1 (en) | Deuterated compounds and chimeras and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211123 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251204 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260318 |